Company intelligence / Profile preview

Curiox Biosystems

Ownership: Private
Employees: ~54
Development stage: Commercial

Overview

Curiox Biosystems develops and commercializes automated sample preparation technologies—such as the C-FREE™, Laminar Wash™, and DropArray™ platforms—that improve efficiency, reproducibility, and data quality in cell-based assays. Their solutions eliminate centrifugation steps in suspension cell prep workflows using laminar flow washing and pipette-based automation. These products are widely used in research labs for applications including flow cytometry, mass cytometry, multiplex immunoassays, drug discovery research, diagnostics development, and primary cell screens. The company went public on Korea’s KOSDAQ exchange in 2023.

Modalities: DeviceAutomated sample preparation platform
Industry: Pathology

Partnerships

University of PennsylvaniaStanford University’s Human Immune Monitoring Center

Beyond the preview

Go deeper on Curiox Biosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curiox Biosystems.

Explore the full profile